Highly Potent HIV-1 Protease Inhibitors

Bookmark/Download	Download as PDF
Track Code	2019-GHOS-68467
Categories	Biotechnology Pharmaceuticals
Keywords	Antiretrovirals Darunavir drugs HIV/AIDS Inhibitors Ligands potent protease small molecules
Public Abstract	There is a need to develop new treatments for patients living with HIV-1, as HIV-1 rapidly acquires resistance to treatment options. Researchers at Purdue University have developed a new class of HIV-1 protease inhibitors. Compared to darunavir, a leading FDA approved drug, these compounds were 100 times more potent in cell culture. Additionally, the compounds have improved metabolic stability over previous protease inhibitors. The primary application for these compounds is for the treatment of multidrug-resistant HIV-1. Advantages: -Improved potency against HIV-1 -Improved pharmacokinetic properties Potential Applications: -HIV/AIDS treatment Publication: Design, Synthesis, and X-ray Studies of Potent HIV-1 Protease Inhibitors with P2-Carboxamide Functionalities ACS Med. Chem. Lett. 2020, 11, 1965−1972 https://doi.org/10.1021/acsmedchemlett.9b00670
People	Ghosh, Arun K (Project leader) Mitsuya, Hiroaki
Intellectual Property	Application Date Jul 15, 2021 Type NATL-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Jan 15, 2020 Type PCT-Gov. Funding Country of Filing WO Patent Number (None) Issue Date (None) Application Date Jan 15, 2020 Type NATL-Patent Country of Filing Europe Patent Number (None) Issue Date (None) Application Date Jan 15, 2019 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None)
Contact OTC	Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org